Imran Syed

Imran Syed

Active Director Director DIN 01154968
DIN 01154968 First appointment Jun 2024 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value •••• Premium profile

About Imran Syed

Data last updated:

Imran Syed is a Director at Bibi Oncology Services Private Limited (since 2024). The company operates in Healthcare. Bibi Oncology Services Private Limited reported revenue of ₹9.14 Cr (FY 2025).

DIN 01154968
Primary Designation Director
Industry Healthcare
First Appointment 24 Jun 2024
Oldest Company Age 11 yrs
Largest company Bibi Oncology Services Private Limited · ₹9.14 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Jun 20242015₹9.14 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Bibi Oncology Services Private Limited
Premium access

Shareholding and investment profile for Imran Syed

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Imran Syed

Imran Syed currently holds 1 directorship: Bibi Oncology Services Private Limited (Director, since 24 Jun 2024, revenue ₹9.14 Cr (FY 2025)).

Imran Syed was first appointed on 24 Jun 2024 as Director at Bibi Oncology Services Private Limited.

The current boards of Imran Syed's companies include Khatija Syed (Bibi Oncology Services Private Limited), Nisar Alam Syed (Bibi Oncology Services Private Limited), Syed Tashreefullah (Bibi Oncology Services Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available